Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial

NCT04355962 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT04355962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04355962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial
Lead sponsor
University of Zurich
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2020
Completion date
July 16, 2021
Enrollment
68 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ards, human, coronavirus